Achieving Market Access & Maximizing Commercial Performance in Turkey, Middle East & North Africa
14th June 2012 — 15th June 2012

Enabling greater market penetration and commercial effectiveness in an exciting and rapidly growing region

During the last few years macro-economic factors such as severe recession, decreasing tax revenues, and high government debt are immensely impacting healthcare budgets across the developed world and provoking aggressive cost-containment in different countries. The high-income countries are the most affected by the crisis on top of their already ageing population and explosion in healthcare costs, so it is no surprise that fast-growing emerging markets are now a major priority for the pharmaceutical industry.

Turkey, The Middle East and North Africa are one of the regions with great potential yet to be fully explored and there is also a high potential for more political and economic liberalization after the “Arab Spring”. The region, with more than 450 million inhabitants, is forecasted to have a 7-10% growth in its healthcare market in 2012 and the middle classes are growing rapidly, increasing affordability for advanced medicine. During the last 5 years “TMENA” experienced economic growth fuelled by general increases on the healthcare expenditures and liberalization of healthcare sector to a larger part of the population by several governments such as Turkey, Egypt, Saudi Arabia, Jordan and Morocco.

However, to fully access these markets and their patients, a deeper understanding is required of the health system structure, regulations, and key stakeholders involved in the process to plan a tailored approach. Much market potential  exists in primary as well as specialty care, and approaches to reach out to more key stakeholders can expand patient access into new niche markets. HTA is in its infancy in this region, but is developing quickly, promising the requirement for more pharmacoeconomic demonstration of value to key decision makers.

This event will provide participants with a broader overview, as well as specific detail of the market access, pricing and reimbursement environment in the region. Furthermore attendees will understand how to communicate with, engage and provide added-value to different stakeholders in order to enhance commercial, marketing performance and sales force effectiveness in key countries such as Turkey, Egypt, Saudi Arabia, United Arab Emirates, Jordan, Algeria and Morocco. A thorough understanding of this dynamic region will be achieved by hearing the perspectives of payers, government officials and key opinion leaders from academia, as well as learning from the case-study experiences from pharma industry veterans who have successfully overcome challenges to launch innovative medicines in this exciting region.

Why attend?

• Learn more about how pricing and reimbursement decision making process works in the main countries in the region and the perspective of using pharmacoeconomic studies in the process.
• Explore innovative approaches to market access in TMENA by understanding how policy makers, pharma manufacturers and academics are perceiving market access, pricing and reimbursement models in the region.
• Understand the multi-stakeholder environment and the best ways of managing and engaging them in order to have a successful market penetration.
• Learn what the best case practices are in commercial performance and how leading companies are maximizing their sales results in the region.
• Benchmark, network and co-operate with pharma & non-pharma decision makers.

Who Will Benefit?

Pharmaceutical Manufacturers:
Vice-Presidents, Director, Managers involved in: Market Access, Pricing and Reimbursement, Health Outcomes, Health Economics, Payer-Relations, Governmental Affairs, Regulatory Affairs, Regional Directors, Area Managers, Commercial Operations, Commercial Excellence, Sales Force Effectiveness, Marketing and Business Operations.

Solution Providers & Consultants:
CEOs, Business Development, Senior Consultants, Regional Heads

Your Prestigious Speaker Panel:

Pharmaceutical Industry

Global Head of Health Economics & Outcomes Research, Critical Care Business Franchise
Novartis Pharma, Switzerland

(TBC) Executive Director
Celgene, Switzerland

Head of Marketing & Sales Operations Middle East
Bayer Healthcare, Egypt

Managing Director
Eli Lilly, Saudi Arabia

Country Manager
Leo-Pharma, Morocco

Business Operations Lead Gulf Region
Merck Sharp & Dohme, UAE

Regional Director DACH, Turkey & Middle East
Managing Director Germany
Swedish Orphan Biovitrum, Germany

Sales & Marketing Professional
Turkey

Commercial Excellence Manager
GlaxoSmithKline, Morocco

Sales Force Excellence Manager
Sanofi-Aventis, Turkey

Leading Academics

Director of Pharmacoeconomics Research Unit
King Saud University, Saudi Arabia

Pharmacoeconomist
Center for Drug Policy and Evaluation, King Hussein Cancer Center, Jordan

Payers & Policy Makers

Central Administration for Pharmaceutical Affairs
Ministry of Health & Population, Egypt

(TBC)
Head of Pricing
Saudi Food and Drug Authority (SFDA), Riad, Saudi Arabia

Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department
Ministry of Health, UAE

EXPERIENCED SOLUTION PROVIDERS

Partner
Mehmet Gun & Partners, Turkey

Expected Number of Attendees

NA

View Conference Website: Achieving Market Access & Maximizing Commercial Performance in Turkey, Middle East & North Africa

Price of Attendance

n/a

Brochure

View Event Brochure

Location

Istanbul
Istanbul
Istanbul
Turkey
Istanbul